Physician profile
Irfan Budhani
NPI 1609079540
$19,725.87
in general payments reported to CMS, 2019-2025
38 companies · $4,400 in 2025
The $4,400 reported for 2025 was more than what 87% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $878 · 2020: $597 · 2021: $839 · 2022: $7,724 · 2023: $1,029 · 2024: $4,260 · 2025: $4,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,474 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,500 · Travel and Lodging: $991 · Education: $700 · Gift: $23.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,474.08 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,500.00 |
| Travel and Lodging | $991.12 |
| Education | $699.98 |
| Gift | $23.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $12,836.65 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,966.19 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,080.38 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Galvanize Therapeutics, INC | $462.80 | 2024-2025 | Aliya System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.84 | 2019-2024 | Ofev, Stiolto Respimat |
| Mallinckrodt Hospital Products INC. | $297.12 | 2020-2025 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $212.00 | 2021-2025 | Glassia |
| Siemens Medical Solutions USA, INC. | $191.11 | 2025 | Cios Spin |
| Genzyme Corporation | $179.53 | 2020-2025 | |
| Mylan Specialty L.P. | $159.91 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $156.25 | 2019-2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $152.52 | 2021-2024 | Opsumit, Uptravi |
| Sunovion Pharmaceuticals INC. | $133.59 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $127.60 | 2019-2025 | Winrevair, Dificid, Zerbaxa |
| Covidien LP | $123.72 | 2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fisher & Paykel Healthcare INC | $121.30 | 2025 | Fisher & Paykel Healthcare |
| Verona Pharma, INC. | $121.24 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $120.89 | 2019-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Regeneron Healthcare Solutions, INC. | $112.43 | 2019-2025 | Dupixent |
| Olympus America INC. | $109.77 | 2023 | Spiration Valve System |
| United Therapeutics Corporation | $106.93 | 2021-2024 | Tyvaso |
| Insmed, INC. | $88.30 | 2019-2024 | Arikayce |
| Body Vision Medical INC. | $84.70 | 2024 | Lungvision |
| Paratek Pharmaceuticals, INC. | $62.73 | 2023-2025 | Nuzyra |
| Philips North America LLC | $50.11 | 2021-2025 | Vest Therapy Und |
| Gilead Sciences, INC. | $49.26 | 2019-2021 | |
| Abiomed | $45.81 | 2025 | |
| Electromed, INC. | $44.04 | 2019-2025 | Smartvest |
| Genentech USA, INC. | $40.90 | 2019-2024 | Xolair |
| Ani Pharmaceuticals, INC. | $36.30 | 2022 | |
| Advanced Respiratory, INC | $28.98 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $28.95 | 2019 | |
| Vifor Pharma, INC. | $20.75 | 2025 | Zemaira |
| Amgen INC. | $17.85 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.64 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.44 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.45 | 2025 | Lifevest |
| Circassia INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irfan Budhani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.